Table. Baseline Characteristics of Participants in the Women's Health Initiative Trials of Postmenopausal Hormone Therapy.
| Characteristic | No. (%) of Participantsa | |||
|---|---|---|---|---|
| CEE Plus MPA Trial | CEE-Alone Trial | |||
| Active (n = 8506) | Placebo (n = 8102) | Active (n = 5310) | Placebo (n = 5429) | |
| Age at screening, mean (SD), y | 63.2 (7.1) | 63.3 (7.1) | 63.6 (7.3) | 63.6 (7.3) |
| Age group at screening, y | ||||
| 50-59 | 2837 (33.4) | 2683 (33.1) | 1639 (30.9) | 1674 (30.8) |
| 60-69 | 3854 (45.3) | 3655 (45.1) | 2386 (44.9) | 2465 (45.4) |
| 70-79 | 1815 (21.3) | 1764 (21.8) | 1285 (24.2) | 1290 (23.8) |
| Race/ethnicity | ||||
| White | 7141 (84.0) | 6805 (84.0) | 4009 (75.5) | 4075 (75.1) |
| Black | 548 (6.4) | 574 (7.1) | 781 (14.7) | 835 (15.4) |
| Hispanic | 471 (5.5) | 415 (5.1) | 319 (6.0) | 332 (6.1) |
| American Indian | 25 (0.3) | 30 (0.4) | 41 (0.8) | 34 (0.6) |
| Asian/Pacific Islander | 194 (2.3) | 169 (2.1) | 86 (1.6) | 78 (1.4) |
| Unknown | 127 (1.5) | 109 (1.3) | 74 (1.4) | 75 (1.4) |
| >High school diploma or GED | 6272 (74.1) | 5899 (73.3) | 3488 (66.3) | 3678 (68.3) |
| Family income ≥$50 000 | 2447 (30.4) | 2401 (31.4) | 1148 (22.9) | 1167 (22.9) |
| Hormone use | ||||
| Never | 6277 (73.8) | 6022 (74.4) | 2769 (52.2) | 2769 (51.0) |
| Past | 1671 (19.7) | 1587 (19.6) | 1871 (35.2) | 1947 (35.9) |
| Currentb | 554 (6.5) | 490 (6.1) | 669 (12.6) | 709 (13.1) |
| Vasomotor symptoms | ||||
| None | 5162 (61.3) | 4928 (61.5) | 2962 (56.4) | 3004 (56.0) |
| Mild | 2190 (26.0) | 2115 (26.4) | 1377 (26.2) | 1441 (26.9) |
| Moderate or severe | 1072 (12.7) | 974 (12.1) | 913 (17.4) | 917 (17.1) |
| Body mass index, median (IQR)c | 27.5 (24.2-31.7) | 27.5 (24.3-31.7) | 29.2 (25.7-33.7) | 29.2 (25.7-33. |
| Systolic BP, mm Hg, mean (SD) | 127.6 (17.6) | 127.8 (17.5) | 130.4 (17.5) | 130.2 (17.6) |
| Diastolic BP, mm Hg, mean (SD) | 75.6 (9.1) | 75.8 (9.1) | 76.5 (9.2) | 76.5 (9.4) |
| Smoking | ||||
| Never | 4178 (49.6) | 3999 (50.0) | 2723 (51.9) | 2705 (50.4) |
| Past | 3362 (39.9) | 3157 (39.5) | 1986 (37.8) | 2090 (38.9) |
| Current | 880 (10.5) | 838 (10.5) | 542 (10.3) | 571 (10.6) |
| Bilateral oophorectomy | 29 (0.3) | 24 (0.3) | 1938 (39.5) | 2111 (42.0) |
| Medical treatment received | ||||
| Diabetes | 374 (4.4) | 360 (4.4) | 410 (7.7) | 412 (7.6) |
| Hypertension or BP ≥140/90 | 3377 (43.2) | 3283 (42.7) | 2651 (53.3) | 2647 (52.6) |
| High cholesterol requiring medication | 1018 (12.0) | 1027 (12.7) | 763 (14.4) | 829 (15.3) |
| Statin use at baseline | 580 (6.8) | 535 (6.6) | 397 (7.5) | 430 (7.9) |
| Aspirin use (≥80 mg/d) | 1652 (19.4) | 1654 (20.4) | 1050 (19.8) | 1081 (19.9) |
| Medical history | ||||
| Myocardial infarction | 139 (1.6) | 157 (1.9) | 165 (3.1) | 173 (3.2) |
| Angina | 318 (3.8) | 331 (4.1) | 402 (7.6) | 388 (7.2) |
| CABG or PCI | 95 (1.1) | 120 (1.5) | 120 (2.3) | 114 (2.1) |
| Stroke | 61 (0.7) | 77 (1.0) | 76 (1.4) | 92 (1.7) |
| DVT or pulmonary embolism | 79 (0.9) | 62 (0.8) | 87 (1.6) | 84 (1.5) |
| Family history of breast cancerd | 1286 (16.0) | 1175 (15.3) | 892 (17.9) | 870 (17.1) |
Abbreviations: BP, blood pressure; CABG, coronary artery bypass graft; CEE, conjugated equine estrogens; DVT, deep vein thrombosis; GED, general equivalency diploma; IQR, interquartile range; MPA, medroxy progesterone acetate; PCI, percutaneous coronary intervention.
a
Values are reported as No. (%) unless otherwise indicated.
b
Required a 3-month washout period prior to randomization.
c
Calculated as weight in kilograms divided by height in meters squared.
d
Indicates occurrence in paticipant's mother, sister, daughter, or grandmother.